RxDoctor Payments DataLook up a doctor →

Alexander Ramsay, MD

Urology · Charleston, SCNPI 1871592089

Payments from drug & device makers

$10,453in general payments, 2019–2025

Across 283 payments — averaging $36.94 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Astellas Pharma US Inc$3K
  • Dendreon Pharmaceuticals LLC$1K
  • Boston Scientific$461
  • Coloplast$449
  • Sumitomo Pharma America, Inc.$363
  • Neotract Inc.$295
  • plus $4K from 47 others

What the payments were for

  • Consulting fees$2,20021%
  • Food & beverage$8,25379%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$10,453 in reported general payments places this provider in the 75th percentile of 196 urology providers in South Carolina.

See all urology providers in South Carolina

Medicare billing

Part B allowed, 2024
$309,952
Medicare patients
723
Services billed
6,473

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XtandiEnzalutamide79$1,096,669
OrgovyxRelugolix68$180,635
ThiolaTiopronin11$145,779
NubeqaDarolutamide11$140,359
Abiraterone Acetate19$99,050
MyrbetriqMirabegron50$42,135
TrelstarTriptorelin Pamoate12$31,764
GemtesaVibegron26$26,262
Tamsulosin Hcl405$7,685
Solifenacin Succinate63$2,899
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst63$1,861
Potassium Citrate ErPotassium Citrate14$1,646
Finasteride111$1,629
Dutasteride24$953
Alfuzosin Hcl ErAlfuzosin Hcl24$470

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncXtandi, Myrbetriq$3,079$1,138,804129 claims
Sumitomo Pharma America, Inc.Orgovyx, Gemtesa$363$206,89794 claims
BayerNubeqa$108$140,35911 claims
Verity Pharmaceuticals Inc.Trelstar$53$31,76412 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 196 urology providers in South Carolina.

Other urology in Charleston

See the full list for South Carolina

Where these figures come from

Is this you, or does something look wrong? →